All Articles

Bluerock is listing its private real estate fund on the NYSE, offering monthly payouts. Is this a game-changer for retail investors or a risky strategic play?

MetaComp and Stable are building a compliant, high-speed payment network with stablecoins, aiming to disrupt the trillion-dollar cross-border market.

Affluent buyers in Southeast Asia are trading property for lifestyle, fueling a 230% boom in branded residences. Why is experience the new ultimate luxury?

A new healthcare city linked to China's largest western HSR hub promises to revolutionize medical access for millions, blending urban planning with wellness.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

A Chinese startup's tiny new heart pump enters human trials, aiming to disrupt a billion-dollar market and solve a massive unmet need in cardiac care.

A decade-long wait ends as the FDA approves a new 1st-line therapy for HER2+ breast cancer. See how ENHERTU reshapes patient outcomes and market dynamics.

A familiar quit-smoking app has been rebuilt into a powerful research tool, powering Australia's largest cessation trial and setting a new standard.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Boise Cascade's acquisition of Holden Humphrey aims to reshape the Northeast building materials market, consolidating its power and expanding its product lines.

A $1.2M investment isn't just charity; it's a strategic push for 'whole-person health' aimed at fixing the Pacific Northwest's deepest care gaps.

Ford hits the brakes on its aggressive EV plan, pivoting to profitable hybrids and a bold new venture in battery energy storage. What does this mean?

IO Biotech’s cancer vaccine posts impressive 5-year survival data, but a narrow miss in its pivotal trial creates an uncertain path in a competitive market.

Beyond a routine board re-election, Heidmar Maritime is doubling down on an AI-driven strategy to navigate the volatile tanker market. Here's what it means.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

A modest dividend payout belies a massive ambition. Canterbury Park is betting its future not on the track, but on building an entire community around it.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

Varsity Healthcare Partners' new foundation applies investment-grade rigor to its giving, funding charities with measurable health and wellness impacts.

Beyond fiber and 5G, the most vital infrastructure is human talent. A new scholarship is empowering the next generation of innovators to build it.